Alternative molecular formats and therapeutic applications for bispecific antibodies
- PMID: 25637431
- DOI: 10.1016/j.molimm.2015.01.003
Alternative molecular formats and therapeutic applications for bispecific antibodies
Abstract
Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described. Two bispecific antibodies, catumaxomab (Removab(®), anti-EpCAM×anti-CD3) and blinatumomab (Blincyto(®), anti-CD19×anti-CD3) are approved for therapy, and >30 additional bispecific antibodies are currently in clinical development. Many of these investigational bispecific antibody drugs are designed to re_target T cells to kill tumor cells, whereas most others are intended to interact with two different disease mediators such as cell surface receptors, soluble ligands and other proteins. The modular architecture of antibodies has been exploited to create more than 60 different bispecific antibody formats. These formats vary in many ways including their molecular weight, number of antigen-binding sites, spatial relationship between different binding sites, valency for each antigen, ability to support secondary immune functions and pharmacokinetic half-life. These diverse formats provide great opportunity to tailor the design of bispecific antibodies to match the proposed mechanisms of action and the intended clinical application.
Keywords: Antibody engineering; Antibody therapeutics; Bispecific antibodies.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Recombinant bispecific antibodies for cancer therapy.Acta Pharmacol Sin. 2005 Jan;26(1):1-9. doi: 10.1111/j.1745-7254.2005.00008.x. Acta Pharmacol Sin. 2005. PMID: 15659107 Review.
-
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.Expert Opin Biol Ther. 2015;15(8):1093-9. doi: 10.1517/14712598.2015.1041373. Epub 2015 May 13. Expert Opin Biol Ther. 2015. PMID: 25971805 Review.
-
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a _targeted cancer immunotherapy.Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27. Cancer Treat Rev. 2010. PMID: 20347527 Review.
-
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.Mol Immunol. 2007 Mar;44(8):1935-43. doi: 10.1016/j.molimm.2006.09.032. Epub 2006 Nov 2. Mol Immunol. 2007. PMID: 17083975
-
RECRUIT-TandAbs: harnessing the immune system to kill cancer cells.Future Oncol. 2012 Jun;8(6):687-95. doi: 10.2217/fon.12.54. Future Oncol. 2012. PMID: 22764766 Review.
Cited by
-
Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies.Antibodies (Basel). 2024 Feb 1;13(1):10. doi: 10.3390/antib13010010. Antibodies (Basel). 2024. PMID: 38390871 Free PMC article. Review.
-
Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics.Antibodies (Basel). 2021 Mar 30;10(2):13. doi: 10.3390/antib10020013. Antibodies (Basel). 2021. PMID: 33808165 Free PMC article. Review.
-
Evading pre-existing anti-hinge antibody binding by hinge engineering.MAbs. 2016 Nov/Dec;8(8):1536-1547. doi: 10.1080/19420862.2016.1219006. Epub 2016 Aug 9. MAbs. 2016. PMID: 27606571 Free PMC article.
-
CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.Cancers (Basel). 2022 Dec 24;15(1):117. doi: 10.3390/cancers15010117. Cancers (Basel). 2022. PMID: 36612114 Free PMC article. Review.
-
Characterization and analysis of scFv-IgG bispecific antibody size variants.MAbs. 2018 Nov-Dec;10(8):1236-1247. doi: 10.1080/19420862.2018.1505398. Epub 2018 Sep 20. MAbs. 2018. PMID: 30130449 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
